Risk of pancreatitis in patients treated with incretin-based therapies

Diabetologia

Volumn 57, Issue 7, 2014, Pages 1320-1324

  Meier, Juris J ^a   Nauck, Michael A ^b  

^a ST JOSEF HOSPITAL   (Germany)

^b DIABETESZENTRUM BAD LAUTERBERG   (Germany)

Author keywords

Adverse effects; DPP 4 inhibitors; GLP 1 analogues; Incretins; Pancreatitis

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; ANTIDIABETIC AGENT; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR;

ACUTE PANCREATITIS; ARTICLE; DRUG EXPOSURE; DRUG INDUSTRY; HUMAN; INCIDENCE; META ANALYSIS (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; AGONISTS; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; PANCREATITIS; RISK;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; PANCREATITIS; RECEPTORS, GLUCAGON; RISK;

EID: 84903519951     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3231-y     Document Type: Article

References (10)

1. Butler PC, Elashoff M, Elashoff R, Gale EA (2013) A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 36:2118-2125
2. Nauck MA (2013) A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care 36:2126-2132
3. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB (2013) Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 173:534-539
4. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141:150-156
5. Egan AG, Blind E, Dunder K et al (2014) Pancreatic safety of incretin-based drugs - FDA and EMA assessment. N Engl J Med 370:794-797
6. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E (2014) Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials. Diabetes Res Clin Pract 102: 269-275
7. WhiteWB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327-1335
8. Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317-1326
9. Meier JJ (2012) GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8:728-742
10. Pyke C, Heller RS, Kirk RK et al (2014) GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155:1280-1290